Earlier Diagnosis of Peripheral Neuropathy Using A Simple sCreening Tool (ACT)

NCT ID: NCT07163000

Last Updated: 2025-09-09

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Total Enrollment: 150 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2025-05-11
• Study Completion Date: 2026-12-30

Brief Summary

This study is looking at people with diabetes (type 1 and type 2 diabetes) to see how well a short questionnaire, called the ACT, can identify nerve damage in the feet and legs (also known as peripheral neuropathy). The investigators will compare the ACT questionnaire to other commonly used tools (the DN4 and Michigan Neuropathy Screening Instrument) and to an eye-test that detects small nerve fibers in the eye (called corneal confocal microscopy, or CCM).

The main goal is to find out if the ACT questionnaire is accurate in detecting nerve damage and painful nerve damage caused by diabetes.

The investigators will also look at whether changes in blood sugar levels, measured with a continuous glucose monitor (Freestyle Libre 3 and iCan), are linked to nerve pain and small nerve fiber damage.

Detailed Description

This a cross-sectional cohort study in patients with diabetes with the aim of assessing the validity and diagnostic accuracy of the ACT questionnaire in identifying peripheral neuropathy (PN) in patients with diabetes and explore underlying mechanisms for nerve damage. The primary endpoint is to validate the ACT tool in identifying diabetic painful neuropathy against the DN4 questionnaire, Michigan Neuropathy Screening Instrument (MNSI) and in relation to underlying small nerve fibre damage (CCM). And the secondary endpoints include the investigation of the association between glycemic indices using continuous glucose monitoring (CGM- Freestyle Libre 3 and iCan) with neuropathic pain (ACT/DN4/MNSI) and small nerve fibre damage (CCM).

Participants will attend 3 visits and the following will be assessed:

• Visit 1(baseline): Consent, screening, CCM, ACT, MNSI, DN4, CGM (Freestyle Libre 3).
• Visit 2 (14-days follow-up): CGM (freestyle Libre 3), ACT, MNSI, DN4
• Visit 3 (between 1-6 months): CGM (iCan)

Conditions

Peripheral Neuropathy; Painful Neuropathy; Diabetes (DM)

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Eligibility Criteria

Inclusion Criteria

• Patients with diabetes (T1DM and T2DM)
• Age ≥18
• Able to provide consent.
• Able to sit still for corneal confocal microscopy

Exclusion Criteria

• Failure to provide informed consent
• Participants with a history of ocular trauma or previous ocular surgery in the preceding 6 months, are allergic to oxybuprocaine or local anesthetics or unable to cooperate by holding still or placing their chin on an optical device
• Other causes of peripheral neuropathy: vitamin B12 deficiency; hypothyroidism; myeloma.
• Cognitively impaired participants
• Pregnant women
• Nursing women

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Procter and Gamble

INDUSTRY

Sponsor Role: collaborator

Hamad Medical Corporation

INDUSTRY

Sponsor Role: collaborator

Weill Cornell Medical College in Qatar

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Professor Rayaz A. Malik, PhD

Role: PRINCIPAL_INVESTIGATOR

Weill Cornell Medicine - Qatar

Locations

Weill Cornell Medicine-Qatar

Doha, , Qatar

Countries

Qatar

Other Identifiers

24-00029

Identifier Type: -

Identifier Source: org_study_id